Personal Products
Valuation | |
|---|---|
| Market Cap | 11.35 kCr |
| Price/Earnings (Trailing) | 135.96 |
| Price/Sales (Trailing) | 35.43 |
| EV/EBITDA | 94.15 |
| Price/Free Cashflow | -220.99 |
| MarketCap/EBT | 102.19 |
| Enterprise Value | 11.2 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | 5.4% |
| Price Change 1M | -2.5% |
| Price Change 6M | 152.2% |
| Price Change 1Y | 458.2% |
| 3Y Cumulative Return | 15.5% |
| 5Y Cumulative Return | 13.8% |
| 7Y Cumulative Return | 19.2% |
Cash Flow & Liquidity |
|---|
| Revenue (TTM) |
| 320.45 Cr |
| Rev. Growth (Yr) | 105.6% |
| Earnings (TTM) | 83.56 Cr |
| Earnings Growth (Yr) | 196.6% |
Profitability | |
|---|---|
| Operating Margin | 35% |
| EBT Margin | 35% |
| Return on Equity | 21.92% |
| Return on Assets | 18.89% |
| Free Cashflow Yield | -0.45% |
| Cash Flow from Investing (TTM) | 44.91 Cr |
| Cash Flow from Operations (TTM) | -11.37 Cr |
| Cash Flow from Financing (TTM) | -1.46 Cr |
| Cash & Equivalents | 177.42 Cr |
| Free Cash Flow (TTM) | -30.83 Cr |
| Free Cash Flow/Share (TTM) | -1.15 |
Balance Sheet | |
|---|---|
| Total Assets | 442.46 Cr |
| Total Liabilities | 61.01 Cr |
| Shareholder Equity | 381.18 Cr |
| Current Assets | 351.07 Cr |
| Current Liabilities | 49.1 Cr |
| Net PPE | 67.36 Cr |
| Inventory | 42.64 Cr |
| Goodwill | 0.00 |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.05 |
| Debt/Equity | 0.05 |
| Interest Coverage | 39.96 |
| Interest/Cashflow Ops | -3.65 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend Yield | 1.7% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 906.4% |
Size: Market Cap wise it is among the top 20% companies of india.
Past Returns: In past three years, the stock has provided 15.5% return compared to 13.2% by NIFTY 50.
Balance Sheet: Strong Balance Sheet.
Profitability: Very strong Profitability. One year profit margin are 26%.
Growth: Awesome revenue growth! Revenue grew 54.1% over last year and 109.4% in last three years on TTM basis.
Dilution: Company has a tendency to dilute it's stock investors.
Smart Money: Smart money is losing interest in the stock.
Size: Market Cap wise it is among the top 20% companies of india.
Past Returns: In past three years, the stock has provided 15.5% return compared to 13.2% by NIFTY 50.
Balance Sheet: Strong Balance Sheet.
Profitability: Very strong Profitability. One year profit margin are 26%.
Growth: Awesome revenue growth! Revenue grew 54.1% over last year and 109.4% in last three years on TTM basis.
Dilution: Company has a tendency to dilute it's stock investors.
Smart Money: Smart money is losing interest in the stock.
Investor Care | |
|---|---|
| Dividend Yield | 1.7% |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 3.11 |
Financial Health | |
|---|---|
| Current Ratio | 7.15 |
| Debt/Equity | 0.05 |
Technical Indicators | |
|---|---|
| RSI (14d) | 38.08 |
| RSI (5d) | 83.43 |
| RSI (21d) | 48.48 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Sell |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal | Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
Summary of Cupid's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Management Outlook & Key Points:
Outlook:
Major Points:
(Character count: 1,999)
Understand Cupid ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| ADITYA KUMAR HALWASIYA | 32.58% |
| COLUMBIA PETRO CHEM PRIVATE LIMITED | 12.98% |
| SETU SECURITIES PVT LTD | 3.53% |
| CLIFF TREXIM PRIVATE LIMITED | 3.15% |
| VEENA GARG | 2.64% |
| VAJRA MACHINERIES PRIVATE LIMITED | 1.6% |
| MAJESTIC COMMERCIAL PRIVATE LIMITED | 1.45% |
Detailed comparison of Cupid against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| MANKIND | Mankind Pharma | 85.05 kCr | 14.34 kCr | -10.90% | -16.90% | 47.87 | 5.93 | - | - |
| AJANTPHARM | Ajanta Pharma | 35.64 kCr | 5.33 kCr |
Cupid Limited designs, manufactures, markets, and exports male and female condoms in India. The company offers water based lubricant jellies; in vitro diagnostic kits, including rapid diagnostic, viral transport medium, typhoid antibody, syphilis antibody, HIV 1 and 2 kit antibody, dengue IgG/IgM Antibody, malaria Pf-Pv and Pf-PAN antigen, hepatitis B (HbsAg) antigen, hepatitis C (HCV) antibody, pregnancy hCG detection, LH ovulation rapid, and dengue NS1 test; and deodorant and pocket perfumes. It also exports its products to countries in Africa, Europe, Ocenia, Asia, North America, and South America. The company was formerly known as Cupid Condom Limited and changed its name to Cupid Limited in January 2006. The company was incorporated in 1993 and is based in Nashik, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
Question 1:
"My question is regarding the warrants which you have issued to the FIIs around Rs. 385 crores. As you have already highlighted that you don't need any money outside, whatever money which is there in the balance sheet is sufficient for expansion of the new facility. So would like to know exactly what's the purpose of raising this Rs. 385 crores. I mean you would be saying that for future need and all that but I would like to know the exact reason for this. Any acquisition you are planning or anything else?"
Answer:
The funds will partially address working capital needs but primarily finance strategic acquisitions in condoms (polyisoprene/polyurethane variants) and IVDs. The goal is to expand product lines, secure faster regulatory approvals, and enhance manufacturing capabilities. Acquisitions are expected within 18 months, targeting companies with existing infrastructure or approvals.
Question 2:
"What is the current order book of the company and can you please split it out in terms of domestic and international market?"
Answer:
The order book stands at Rs. 80 crores, with 85"“90% from international markets (including female condom orders from South Africa/Brazil and male condoms for UNFPA) and 10"“15% domestic (primarily male condoms and IVD kits). Deliveries are expected over the next 12 months.
Question 3:
"What is your competitor profile for IVD?"
Answer:
Cupid's IVD segment focuses on 8 test kits, including malaria and pregnancy (Cupisure). Clinical trials and CE/WHO certifications for malaria kits are underway, with domestic tender participation expected by mid-2024 and global orders (Africa/Latin America) targeted post-2025 after approvals.
Question 4:
"What is the current order book of the company and can you please split it out in terms of domestic and international market?"
Answer:
The order book stands at Rs. 80 crores, with 85"“90% from international markets (including female condom orders from South Africa/Brazil and male condoms for UNFPA) and 10"“15% domestic (primarily male condoms and IVD kits). Deliveries are expected over the next 12 months.
Question 5:
"Quantified in revenue and profitability terms, what are we expecting from the capacity expansion announced by the company in December?"
Answer:
Post-expansion, Cupid projects revenue of $400 million (Rs.3,200 crores) and EBITDA exceeding $100 million (Rs.800 crores). This includes new condom lines (300 million units added to 480 million existing capacity) and leveraging acquisitions for premium product diversification.
| RADHARANI SALES PRIVATE LIMITED | 1.34% |
| GARG BROTHERS PRIVATE LIMITED | 1.3% |
| HIGHPOINT COMMERCIAL PRIVATE LIMITED | 1.27% |
| AJAY KUMAR HALWASIYA | 0% |
| JAIDEEP HALWASIYA | 0% |
| EKTA HALWASIYA | 0% |
| ANKITA JAIN HALWASIYA | 0% |
| Universal Petrochemicals Limited | 0% |
| Adar Hotels Private Limited | 0% |
| ABDULMUHSIN SUHNI | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
| 0.00% |
| +5.70% |
| 35.14 |
| 6.69 |
| - |
| - |
| PFIZER | Pfizer | 21 kCr | 2.57 kCr | -6.90% | +4.00% | 25.02 | 8.17 | - | - |
| 58 |
| 45 |
| 45 |
| 37 |
| - |
| Profit Before exceptional items and Tax | 35.5% | 43 | 32 | 20 | 16 | 14 | - |
| Total profit before tax | 35.5% | 43 | 32 | 20 | 16 | 14 | - |
| Current tax | 16.5% | 9.11 | 7.96 | 5.12 | 4.59 | 3.03 | - |
| Deferred tax | 136.7% | 1.33 | 0.1 | -0.58 | -0.1 | -0.02 | - |
| Total tax | 27.5% | 10 | 8.06 | 4.54 | 4.49 | 3.01 | - |
| Total profit (loss) for period | 39.1% | 33 | 24 | 15 | 12 | 11 | - |
| Other comp. income net of taxes | 18% | 0 | -0.22 | 0 | -1.18 | 0 | - |
| Total Comprehensive Income | 39.1% | 33 | 24 | 15 | 10 | 11 | - |
| Earnings Per Share, Basic | 320% | 1.22 | 0.9 | 0.56 | 0.43 | 0.411 | - |
| Earnings Per Share, Diluted | 300% | 1.22 | 0.89 | 0.55 | 0.42 | 0.41 | - |
| 29 |
| 16 |
| 14 |
| 11 |
| 10 |
| 8.74 |
| Finance costs | 29.6% | 2.05 | 1.81 | 0.79 | 0.13 | 0.39 | 0.53 |
| Depreciation and Amortization | 80.3% | 4.48 | 2.93 | 2.97 | 2.65 | 2.6 | 2.5 |
| Other expenses | 0% | 45 | 45 | 39 | 37 | 47 | 58 |
| Total Expenses | 17.6% | 148 | 126 | 122 | 113 | 111 | 112 |
| Profit Before exceptional items and Tax | 3.8% | 55 | 53 | 42 | 25 | 38 | 53 |
| Total profit before tax | 3.8% | 55 | 53 | 42 | 25 | 38 | 53 |
| Current tax | 8.3% | 14 | 13 | 10 | 7.09 | 9.91 | 13 |
| Deferred tax | -17.4% | -0.01 | 0.14 | 0.52 | 0.15 | -0.69 | -0.21 |
| Total tax | 8.3% | 14 | 13 | 11 | 7.24 | 9.22 | 13 |
| Total profit (loss) for period | 2.6% | 41 | 40 | 32 | 17 | 29 | 40 |
| Other comp. income net of taxes | -64.2% | -1.43 | -0.48 | -0.12 | 0.06 | -0.26 | -0.25 |
| Total Comprehensive Income | 2.6% | 40 | 39 | 31 | 17 | 29 | 40 |
| Earnings Per Share, Basic | 6.1% | 1.52 | 1.49 | 11.84 | 6.475 | 10.865 | 14.935 |
| Earnings Per Share, Diluted | 5.2% | 1.51 | 1.485 | 11.785 | 6.475 | 10.865 | 14.935 |
| 36.8% |
| 8.51 |
| 6.49 |
| 0.42 |
| 0 |
| 0 |
| 0 |
| Non-current investments | -13.3% | 14 | 16 | 12 | 0 | 0 | 0 |
| Total non-current financial assets | -12.5% | 15 | 17 | 12 | 0 | 0 | 0 |
| Total non-current assets | 1.1% | 91 | 90 | 82 | 58 | 36 | 36 |
| Total assets | 18.9% | 442 | 372 | 359 | 320 | 212 | 189 |
| Borrowings, non-current | - | 4.94 | 0 | 0 | 0 | 0 | 0 |
| Total non-current financial liabilities | - | 4.94 | 0 | 0 | 0 | 0 | 0 |
| Provisions, non-current | -16.3% | 2.28 | 2.53 | 0.23 | 0.32 | 0 | 0.21 |
| Total non-current liabilities | 48.8% | 12 | 8.39 | 7.83 | 1.65 | 0.43 | 1.55 |
| Borrowings, current | 25% | 16 | 13 | 9.04 | 12 | 9.36 | 5.97 |
| Total current financial liabilities | 118.8% | 36 | 17 | 23 | 15 | 35 | 17 |
| Provisions, current | - | 1.02 | 1 | 0.56 | 1.1 | 1.28 | 0.54 |
| Current tax liabilities | 2776.5% | 5.89 | 1.17 | 5.66 | 0 | 0 | 0.31 |
| Total current liabilities | 140% | 49 | 21 | 30 | 17 | 40 | 20 |
| Total liabilities | 106.9% | 61 | 30 | 38 | 19 | 41 | 22 |
| Equity share capital | 0% | 27 | 27 | 27 | 13 | 13 | 13 |
| Total equity | 11.4% | 381 | 342 | 321 | 301 | 171 | 167 |
| Total equity and liabilities | 18.9% | 442 | 372 | 359 | 320 | 212 | 189 |
| 0% |
| 13 |
| 13 |
| 11 |
| 8.82 |
| - |
| - |
| Net Cashflows From Operating Activities | -277.5% | -11.14 | 7.84 | 33 | 10 | - | - |
| Cashflows used in obtaining control of subsidiaries | - | 0.23 | 0 | 0 | 0 | - | - |
| Proceeds from sales of PPE | - | 0 | 0 | 0.04 | 0 | - | - |
| Purchase of property, plant and equipment | -79.5% | 19 | 89 | 2.54 | 8.64 | - | - |
| Interest received | 309.8% | 16 | 4.66 | 4.14 | 2.96 | - | - |
| Other inflows (outflows) of cash | 1133.9% | 49 | 4.89 | -23.5 | -7.82 | - | - |
| Net Cashflows From Investing Activities | 154.4% | 45 | -79.84 | -21.86 | -13.49 | - | - |
| Proceeds from issuing other equity instruments | -101% | 0 | 98 | 0 | 0 | - | - |
| Proceeds from exercise of stock options | - | 0.01 | 0 | 0 | 0 | - | - |
| Proceeds from borrowings | -108.3% | 0.58 | 6.08 | 0 | 8.8 | - | - |
| Repayments of borrowings | - | 0 | 0 | 2.82 | 0 | - | - |
| Dividends paid | -133.3% | 0 | 4 | 7.34 | 6 | - | - |
| Interest paid | 29.6% | 2.05 | 1.81 | 0.79 | 0.13 | - | - |
| Net Cashflows from Financing Activities | -102.5% | -1.46 | 99 | -10.95 | 2.66 | - | - |
| Net change in cash and cash eq. | 19.2% | 32 | 27 | -0.1 | -0.59 | - | - |
Analysis of Cupid's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
No revenue data available.